Pancreatic Cancer Research

ResearcherGuiyang Medical UniversityActive in the last 2 years

Liwen Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4705-4754; OpenAlex author ID A5100730194. Sources: OpenAlex.

Their work

Papers
3
Trials
0
Grants
0
Labs led
0
Collaborators
11
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 3

  1. HOXC9 enhances cholesterol metabolism and malignancy in pancreatic ductal adenocarcinoma through ITGA10/FAK/PI3K/CREB-dependent HMGCR activation. Co-author DOI 10.1007/s00535-026-02457-7↗
  2. HOXC4 promotes proliferation of pancreatic cancer cells by increasing LDHA-mediated glycolysis. Co-author DOI 10.18632/aging.206008↗
  3. Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway. Co-author DOI 10.3892/or.2018.6198↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dijie Zheng · 1 shared paper, 2026 · strength 0.30
  2. Futang Li · 1 shared paper, 2026 · strength 0.30
  3. Xinghao Sun · 1 shared paper, 2026 · strength 0.30
  4. Chao Yu · 1 shared paper, 2026 · strength 0.30
  5. She Tian · 1 shared paper, 2024 · strength 0.26
  6. Li Liu · 1 shared paper, 2024 · strength 0.26
  7. Hao Zhang · 1 shared paper, 2024 · strength 0.26
  8. Qianfan Liu · 1 shared paper, 2018 · strength 0.08
  9. Zili Chen · 1 shared paper, 2018 · strength 0.08
  10. Chengyi Sun · 1 shared paper, 2018 · strength 0.08
  11. Haitao Zhu · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.